BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,321,393 | -19.2% | 61,510 | -2.5% | 0.00% | -20.0% |
| Q2 2023 | $2,873,497 | -0.3% | 63,071 | -11.2% | 0.01% | 0.0% |
| Q1 2023 | $2,880,856 | -19.7% | 71,027 | +0.9% | 0.01% | -28.6% |
| Q4 2022 | $3,588,877 | -22.9% | 70,411 | -18.6% | 0.01% | -30.0% |
| Q3 2022 | $4,657,000 | -22.8% | 86,469 | -7.9% | 0.01% | -23.1% |
| Q2 2022 | $6,030,000 | -12.6% | 93,884 | +5.5% | 0.01% | 0.0% |
| Q1 2022 | $6,903,000 | +3.5% | 89,022 | +14.6% | 0.01% | +8.3% |
| Q4 2021 | $6,669,000 | +0.1% | 77,687 | -6.2% | 0.01% | -7.7% |
| Q3 2021 | $6,661,000 | +3.3% | 82,820 | +3.4% | 0.01% | 0.0% |
| Q2 2021 | $6,448,000 | -2.7% | 80,103 | +2.0% | 0.01% | -13.3% |
| Q1 2021 | $6,626,000 | +6.7% | 78,563 | +1.5% | 0.02% | -6.2% |
| Q4 2020 | $6,209,000 | +6.2% | 77,376 | +6.5% | 0.02% | -5.9% |
| Q3 2020 | $5,845,000 | -7.0% | 72,680 | -0.4% | 0.02% | -15.0% |
| Q2 2020 | $6,283,000 | +4.1% | 72,975 | -1.8% | 0.02% | -23.1% |
| Q1 2020 | $6,033,000 | -33.3% | 74,309 | -31.3% | 0.03% | -10.3% |
| Q4 2019 | $9,048,000 | -9.1% | 108,200 | -4.9% | 0.03% | -19.4% |
| Q3 2019 | $9,953,000 | +18.7% | 113,782 | +11.2% | 0.04% | +12.5% |
| Q2 2019 | $8,383,000 | +3.6% | 102,355 | +2.8% | 0.03% | -5.9% |
| Q1 2019 | $8,095,000 | +26.4% | 99,555 | +2.4% | 0.03% | 0.0% |
| Q4 2018 | $6,402,000 | -13.1% | 97,264 | +1.8% | 0.03% | +3.0% |
| Q3 2018 | $7,368,000 | +7.4% | 95,579 | +2.9% | 0.03% | -5.7% |
| Q2 2018 | $6,858,000 | -5.5% | 92,873 | -16.7% | 0.04% | -16.7% |
| Q1 2018 | $7,255,000 | +20.7% | 111,541 | +20.0% | 0.04% | +10.5% |
| Q4 2017 | $6,010,000 | +0.9% | 92,977 | -2.1% | 0.04% | 0.0% |
| Q3 2017 | $5,958,000 | +2.1% | 94,952 | -1.4% | 0.04% | -5.0% |
| Q2 2017 | $5,833,000 | +23.6% | 96,348 | +5.9% | 0.04% | +11.1% |
| Q1 2017 | $4,718,000 | +56.9% | 90,975 | +34.2% | 0.04% | +44.0% |
| Q4 2016 | $3,007,000 | -9.0% | 67,791 | -2.3% | 0.02% | -13.8% |
| Q3 2016 | $3,304,000 | +15.8% | 69,406 | +10.0% | 0.03% | +3.6% |
| Q2 2016 | $2,853,000 | -5.3% | 63,087 | -14.0% | 0.03% | -20.0% |
| Q1 2016 | $3,013,000 | +7.7% | 73,342 | +0.1% | 0.04% | +6.1% |
| Q4 2015 | $2,797,000 | -41.8% | 73,302 | -49.9% | 0.03% | -58.8% |
| Q3 2015 | $4,802,000 | +291.7% | 146,175 | +733.6% | 0.08% | -9.1% |
| Q2 2015 | $1,226,000 | +61.3% | 17,536 | +58.1% | 0.09% | +137.8% |
| Q1 2015 | $760,000 | -10.8% | 11,092 | -4.6% | 0.04% | -15.9% |
| Q4 2014 | $852,000 | +4.3% | 11,630 | +2.2% | 0.04% | 0.0% |
| Q3 2014 | $817,000 | -6.1% | 11,384 | -5.4% | 0.04% | -15.4% |
| Q2 2014 | $870,000 | -21.3% | 12,036 | -19.9% | 0.05% | -20.0% |
| Q1 2014 | $1,106,000 | +11.2% | 15,034 | +5.0% | 0.06% | +6.6% |
| Q4 2013 | $995,000 | -20.1% | 14,313 | -24.5% | 0.06% | -25.6% |
| Q3 2013 | $1,245,000 | -62.2% | 18,947 | -60.2% | 0.08% | -14.6% |
| Q2 2013 | $3,298,000 | – | 47,617 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |